Publications by authors named "Masaki Seto"

Claim this Profile
D
Discovery of Brain-Penetrant Glucosylceramide Synthase Inhibitors with a Novel Pharmacophore.
Yuta Tanaka, Masaki Seto, Keiko Kakegawa, Kazuaki Takami, Fumiaki Kikuchi

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyrazolo[1,5-a]pyrazin-4-ones as Potent and Brain Penetrant GluN2A-Selective Positive Allosteric Modulators Reducing AMPA Receptor Binding Activity.
Fumie Sakurai, Takafumi Yukawa, Asato Kina, Masataka Murakami, Kazuaki Takami, Masaki Seto

Bioorg Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists.
Takuto Kojima, Michiyo Mochizuki, Takafumi Takai, Yasutaka Hoashi, Sachie Morimoto, Masaki Seto

Bioorg Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Design and Synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one Derivatives as Tyrosine Kinase 2 Inhibitors.
Takatoshi Yogo, Hiroyuki Nagamiya, Masaki Seto, Satoshi Sasaki, Huang Shih-Chung

J Med Chem· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formal total syntheses of classic natural product target molecules via palladium-catalyzed enantioselective alkylation.
Yiyang Liu, Marc Liniger, Ryan M McFadden, Jenny L Roizen, Jacquie Malette, Masaki Seto

Beilstein J Org Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors.
Youichi Kawakita, Masaki Seto, Tomohiro Ohashi, Toshiya Tamura, Tadashi Yusa

Bioorg Med Chem· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.
Youichi Kawakita, Kazuhiro Miwa, Masaki Seto, Hiroshi Banno, Yoshikazu Ohta

Bioorg Med Chem· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.
Tomoyasu Ishikawa, Masaki Seto, Hiroshi Banno, Youichi Kawakita, Mami Oorui

J Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enantioselective decarboxylative alkylation reactions: catalyst development, substrate scope, and mechanistic studies.
Douglas C Behenna, Justin T Mohr, Nathaniel H Sherden, Smaranda C Marinescu, Andrew M Harned, Masaki Seto

Chemistry· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Catalytic enantioselective alkylation of substituted dioxanone enol ethers: ready access to Calpha-tetrasubstituted hydroxyketones, acids, and esters.
Masaki Seto, Jennifer L Roizen, Brian M Stoltz

Angew Chem Int Ed Engl· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Masaki Seto, Katsuji Aikawa, Naoki Miyamoto, Yoshio Aramaki, Naoyuki Kanzaki

J Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety.
Masaki Seto, Naoki Miyamoto, Katsuji Aikawa, Yoshio Aramaki, Naoyuki Kanzaki

Bioorg Med Chem· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active CCR5 antagonists as anti-HIV-1 agents 2: synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety.
Masaki Seto, Yoshio Aramaki, Hiroshi Imoto, Katsuji Aikawa, Tsuneo Oda

Chem Pharm Bull (Tokyo)· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activity of 1-benzothiepine 1,1-dioxide and 1-benzazepine derivatives containing a tertiary amine moiety.
Masaki Seto, Yoshio Aramaki, Tomohiro Okawa, Naoki Miyamoto, Katsuji Aikawa

Chem Pharm Bull (Tokyo)· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of 1-benzothiepine and 1-benzazepine derivatives as orally active CCR5 antagonists.
Yoshio Aramaki, Masaki Seto, Tomohiro Okawa, Tsuneo Oda, Naoyuki Kanzaki

Chem Pharm Bull (Tokyo)· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis